Malaysia's Proposed Ban on E-cigarettes Criticized by Doctor Association

Aug.01.2022
Malaysia's Proposed Ban on E-cigarettes Criticized by Doctor Association
Malaysia doctors criticize government proposal to ban e-cigarettes as a harm reduction tool for smokers.

KUALA LUMPUR, AUGUST 1 - A medical association has criticized the government's proposal to ban the promotion of e-cigarettes as a tobacco harm reduction alternative.


The Federation of Private Medical Practitioners' Association Malaysia (FPMPAM) has highlighted New Zealand and Australia's Tobacco Harm Reduction (THR) plans. New Zealand's plan includes a generational tobacco ban for those born after 2009, but it exempts electronic cigarettes as they are promoted as a tool to help smokers quit. However, Malaysia's "Generational Endgame for Tobacco Products and Smoking" (GEG) proposed in the 2022 tobacco products and smoking bill prohibits the sale, possession, and consumption of tobacco products to anyone born after 2007 and also bans electronic cigarettes, regardless of whether the e-liquid contains nicotine or not.


Dr. Steven Chow, the President of FPMPAM, stated today in a release, "The bill appears to completely disregard the overwhelming scientific data that shows THR can work within an appropriate regulatory framework.


Dr. Steven Chow, Chairman of the Federation of Private Medical Practitioners' Associations Malaysia (FPMPAM)


This was extensively documented in the Royal College of Physicians' 2016 report titled "Nicotine Without Smoke: Reducing the Harm of Tobacco".


According to a report released by the Royal College of Physicians (RCP) in the UK, electronic cigarettes seem to be effective as a smoking cessation aid when used by smokers. The report suggests that the long-term health risks associated with inhaling e-cigarette vapour are unlikely to exceed 5% of the risks associated with smoking.


The Royal College of Physicians (RCP) has stated that it is necessary to regulate the use of electronic cigarettes in order to reduce their direct and indirect harmful effects. However, the RCP warns against significantly restricting the use of harm-reducing products by smokers through such regulations.


However, for public health, it is important to promote as widely as possible the use of electronic cigarettes, nicotine replacement therapy (NRT), and other non-tobacco nicotine products as substitutes for smoking.


Dr. Zhou pointed out that section 9(1) of the 2022 Tobacco Products and Smoking Control Bill will prohibit the promotion or sponsorship of electronic cigarette products as smoking cessation aids. This will effectively prevent the dissemination of information regarding tobacco harm reduction, such as discussions on the UK's RCP report.


Individuals who fail to comply with Section 9(1) may face a fine of up to RM20,000, a maximum sentence of one year imprisonment, or both, upon first conviction. Corporate entities may be fined between RM20,000 to RM100,000, face imprisonment for a maximum of two years, or face a fine upon the first offence after conviction.


Dr. Zhou stated, "The legislators from both sides of the House should carefully review this authoritative document and consider implementing policies that have already proven effective before starting to enforce GEG.


Pushing GEG without this preparation work would be a risky social experiment.


The Malaysian Medical Association (FPMPAM) has criticized the proposal to criminalize the possession and consumption of cigarettes, tobacco or electronic cigarettes by individuals born after January 1, 2007. FPMPAM describes this as a key provision in the Tobacco Control Bill.


Once convicted, these crimes may result in fines of up to RM 5000. If the Global E-cigarette and Tobacco Law is enforced starting from 2025, this means that adolescents and children aged 18 and below who are caught smoking, using e-cigarettes, or possessing tobacco or e-cigarette devices will face enforcement and prosecution.


Smoking, vaping, and using tobacco products have significant health consequences and are addictive diseases. Like all addicts, they require appropriate medical intervention and treatment from specially trained professionals, rather than being convicted as criminals, said FPMPAM.


The medical association has pointed out that their experience in community-based treatment for opioid addiction shows that a network of specially trained national general practitioners (GPs) and family doctors is best suited to manage this issue.


For children caught attempting to smoke or use e-cigarettes, they are also the best care points. However, the bill lacks provisions to promote and authorize healthcare professionals to complete this task.


I'm sorry, but without context or a specific text to refer to, I cannot provide a translation. Please provide more information or the original text.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
Science | International Experts Propose a New Smoking Cessation Pathway, Citing Higher Quit Rates With E-Cigarettes Than Nicotine Replacement Therapy
Science | International Experts Propose a New Smoking Cessation Pathway, Citing Higher Quit Rates With E-Cigarettes Than Nicotine Replacement Therapy
A new expert paper in JAMA urges U.S. clinicians to include nicotine e-cigarettes in smoking-cessation discussions, citing higher quit rates than nicotine replacement therapy. It also stresses that products must deliver enough nicotine to replace cigarettes, dual use should be brief, and complete switching is the goal. 2Firsts argues the recommendations matter beyond clinics: public-health professionals should reassess relative risk, regulators should preserve sufficient product appeal for adult smokers, and manufacturers should focus on helping users quit cigarettes more sustainably.
SCIENCE
Aug.03 by 2Firsts Perspectives
Florida Governor DeSantis Expands TANF Restrictions, Blocking Welfare Benefits From Buying Tobacco and Vapes
Florida Governor DeSantis Expands TANF Restrictions, Blocking Welfare Benefits From Buying Tobacco and Vapes
Florida Governor Ron DeSantis announced an expansion of Temporary Assistance for Needy Families (TANF) restrictions that would prohibit Electronic Benefit Transfer (EBT) funds from being used to purchase tobacco and vaping products. The state will amend its TANF State Plan and submit the changes for federal approval. Florida officials said the restrictions would not affect eligibility for temporary cash assistance or the amount of benefits received, but would change how funds can be spent.
Aug.25
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
French vaping company Kumulus Vape reported first-half 2026 revenue of €25.5 million, down 8.3% year over year, as its core B2B distribution business fell 11% to €21.6 million. B2C and store-network revenue rose 5.6% and 17.8%, respectively. Commercial margin increased to 26.3% from 21.7%, while net profit rose 24.1% to €0.8 million. The company attributed the profitability improvement to catalog optimization, logistics restructuring and the ramp-up of Labster, its in-house production unit for proprietary brands.
Market
Sep.17 by 2Firsts Perspectives
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
The FDA authorized the JUUL2 device and tobacco- and menthol-flavored pods on Aug. 28, bringing the number of authorized e-cigarette products to 48. The agency highlighted complete switching among adult smokers, with six-week switching rates reaching 28.4%–49.3% for the menthol pod. The decision comes as FDA works to speed PMTA reviews, reduce application backlogs and expand authorized e-cigarette and nicotine-pouch products while maintaining enforcement priorities for unauthorized products.
Regulations
Aug.29
Product | Philip Morris Japan Launches Ginza-Exclusive IQOS ILUMA i PRIME, Limited to 1,814 Units at First Global Flagship
Product | Philip Morris Japan Launches Ginza-Exclusive IQOS ILUMA i PRIME, Limited to 1,814 Units at First Global Flagship
Philip Morris Japan (PMJ) launched the IQOS ILUMA i PRIME Ginza Limited Model Set in Tokyo on September 4, 2026, alongside the opening of IQOS Flagship Ginza, the brand’s first global flagship store. The Oasis Blue edition is limited to 1,814 individually numbered units, with the figure derived from the store’s address at Ginza 1-8-14. The set also includes two Yamanaka-nuri glasses and special packaging, priced at JPY 11,980 and sold exclusively at the Ginza flagship.
Sep.07